Enanta Pharmaceuticals (ENTA) Revenue & Revenue Breakdown
Enanta Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$67.64M
Latest Revenue (Q)
$17.97M
Main Segment (Y)
Royalty
Main Geography (Y)
Royalty
Enanta Pharmaceuticals Revenue by Period
Enanta Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $67.64M | -14.61% |
| 2023-09-30 | $79.20M | -8.07% |
| 2022-09-30 | $86.16M | -11.24% |
| 2021-09-30 | $97.07M | -20.74% |
| 2020-09-30 | $122.47M | -40.31% |
| 2019-09-30 | $205.20M | -0.69% |
| 2018-09-30 | $206.63M | 100.97% |
| 2017-09-30 | $102.81M | 16.48% |
| 2016-09-30 | $88.27M | -45.13% |
| 2015-09-30 | $160.88M | 236.98% |
| 2014-09-30 | $47.74M | 48.94% |
| 2013-09-30 | $32.05M | -23.15% |
| 2012-09-30 | $41.71M | -0.42% |
| 2011-09-30 | $41.88M | 83.99% |
| 2010-09-30 | $22.76M | - |
Enanta Pharmaceuticals generated $67.64M in revenue during NA 2024, up -14.61% compared to the previous quarter, and up 32.96% compared to the same period a year ago.
Enanta Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $17.97M | 5.38% |
| 2024-03-31 | $17.05M | -5.27% |
| 2023-12-31 | $18.00M | -4.91% |
| 2023-09-30 | $18.93M | 0.21% |
| 2023-06-30 | $18.89M | 6.16% |
| 2023-03-31 | $17.80M | -24.55% |
| 2022-12-31 | $23.59M | 16.09% |
| 2022-09-30 | $20.32M | 4.30% |
| 2022-06-30 | $19.48M | 4.08% |
| 2022-03-31 | $18.72M | -32.31% |
| 2021-12-31 | $27.65M | 17.28% |
| 2021-09-30 | $23.57M | 9.02% |
| 2021-06-30 | $21.62M | 7.41% |
| 2021-03-31 | $20.13M | -36.58% |
| 2020-12-31 | $31.74M | 34.33% |
| 2020-09-30 | $23.63M | 26.69% |
| 2020-06-30 | $18.65M | -32.46% |
| 2020-03-31 | $27.62M | -47.46% |
| 2019-12-31 | $52.57M | 2.45% |
| 2019-09-30 | $51.31M | 15.66% |
| 2019-06-30 | $44.37M | 11.95% |
| 2019-03-31 | $39.63M | -43.29% |
| 2018-12-31 | $69.89M | 3.99% |
| 2018-09-30 | $67.20M | 17.36% |
| 2018-06-30 | $57.26M | 30.00% |
| 2018-03-31 | $44.05M | 15.59% |
| 2017-12-31 | $38.11M | -49.81% |
| 2017-09-30 | $75.93M | 910.88% |
| 2017-06-30 | $7.51M | -16.16% |
| 2017-03-31 | $8.96M | -14.00% |
| 2016-12-31 | $10.42M | -18.88% |
| 2016-09-30 | $12.84M | -8.13% |
| 2016-06-30 | $13.98M | 7.49% |
| 2016-03-31 | $13.00M | -73.16% |
| 2015-12-31 | $48.45M | 236.05% |
| 2015-09-30 | $14.42M | 24.29% |
| 2015-06-30 | $11.60M | -79.78% |
| 2015-03-31 | $57.37M | -25.98% |
| 2014-12-31 | $77.50M | 2838.87% |
| 2014-09-30 | $2.64M | -93.73% |
| 2014-06-30 | $42.05M | 1846.81% |
| 2014-03-31 | $2.16M | 141.88% |
| 2013-12-31 | $893.00K | -33.80% |
| 2013-09-30 | $1.35M | -18.19% |
| 2013-06-30 | $1.65M | 37.88% |
| 2013-03-31 | $1.20M | -95.71% |
| 2012-12-31 | $27.86M | 1399.41% |
| 2012-09-30 | $1.86M | -26.91% |
| 2012-06-30 | $2.54M | -93.05% |
| 2012-03-31 | $36.56M | 4834.55% |
| 2011-12-31 | $741.00K | 100.00% |
| 2011-09-30 | - | - |
Enanta Pharmaceuticals generated $17.97M in revenue during Q3 2024, up 5.38% compared to the previous quarter, and up 100.99% compared to the same period a year ago.
Enanta Pharmaceuticals Revenue Breakdown
Enanta Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Sep 24 | Sep 23 | Sep 21 | Sep 20 | Sep 19 |
|---|---|---|---|---|---|
| Royalty | $67.64M | $78.20M | $97.07M | $122.47M | $205.20M |
| License | - | $1.00M | - | - | - |
Enanta Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Sep 24: Royalty (100.00%).
Quarterly Revenue by Product
| Product/Service | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalty | $32.58M | $17.05M | $18.00M | $18.93M | $18.89M | $17.80M | $22.59M | $51.31M | $44.37M | $39.63M | $69.89M | $67.20M | $57.26M |
| License | - | - | - | - | - | - | $1.00M | - | - | - | - | - | - |
| Milestone | - | - | - | - | - | - | - | - | - | - | - | - | $15.00M |
Enanta Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Royalty (100.00%).
Enanta Pharmaceuticals Revenue Breakdown by Country
Annual Revenue by Country
| Country | Sep 21 | Sep 20 | Sep 19 | Sep 18 |
|---|---|---|---|---|
| Royalty | $97.07M | $122.47M | $205.20M | $191.63M |
| Milestone | - | - | - | $15.00M |
Enanta Pharmaceuticals's latest annual revenue breakdown by geography, as of Sep 21: Royalty (100.00%).
Enanta Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ENTA | Enanta Pharmaceuticals | $67.64M | $17.97M |
| MRUS | Merus | $43.95M | $11.77M |
| HOWL | Werewolf Therapeutics | $19.94M | $1.14M |
| RVMD | Revolution Medicines | $11.58M | - |
| IKNA | Ikena Oncology | $9.16M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.89M |
| KRON | Kronos Bio | $6.29M | $2.37M |
| CRNX | Crinetics Pharmaceuticals | $4.01M | - |
| IPSC | Century Therapeutics | $2.23M | $791.00K |
| INBX | Inhibrx Biosciences | $1.80M | - |
| LYEL | Lyell Immunopharma | $130.00K | $34.00K |
| DSGN | Design Therapeutics | - | - |
| CGEM | Cullinan Oncology | - | - |
| CCCC | C4 Therapeutics | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| EWTX | Edgewise Therapeutics | - | - |